By Rishika Sadam

July 14 (Reuters) - India's top drugmaker by revenue Sun

Pharma on Monday launched its anti-baldness drug

Leqselvi in the U.S., following the settlement of a patent

dispute with Incyte Corp. ( INCY )

The company said 8 mg Leqselvi tablets for severe alopecia

areata will be available in the U.S., after a launch delay

caused by a patent infringement case in a U.S. court.

Shrikant Akolkar, analyst at Nuvama Institutional Equities,

said the drug could generate up to $400 million in sales by

FY30, with peak sales potential of $900 million, and boost

growth in Sun's key U.S. market.

"This settlement is very positive and there is no overhang

of any legal dispute anymore. The drug has very good clinical

data and with this launch, Sun Pharma's commercial portfolio

broadens further," he said.

India's drugmakers have been grappling with pricing pressure

and stiff competition in the U.S.

The company said the drug's addition to its dermatology

portfolio is a "key milestone", as it focuses on new therapy

areas.

Alopecia areata is an autoimmune disease that causes patchy

hair loss on the scalp and other areas of the body.